← Leaderboards
Glenn Jaffe
Duke University
$4,863,463
Attributed
$5,355,981
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $713.3K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,355,981 · 4
By mechanism
U10$2,339,273 · 1
R01$1,346,629 · 1
UG1$985,037 · 1
M01$685,042 · 1
Top collaborators
- Sina Farsiu4 shared
Most similar at Duke University
Same institution · by research overlap
- Tatiana Segura$14,175,920
- Christina Eleanor Barkauskas$856,145
- Mark N Feinglos$8,642,419
- Virginia B. Kraus$21,094,161
- Kouros Owzar$6,468,635
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchCustomSecureSiteHuman ResourcesScanningTrainingReproducibilityProtocols DocumentationReadingTransmission ProcessResourcesBlindnessDesignArchivesImageEnsureCertificationCharacteristicsClinical TrialsPublicationsElectronicsGroup MeetingsOptical Coherence Tomography
Grant awards (25)
NAC Attack, a phase-3, multicenter, randomized, placebo-controlled trial with retinitis pigmentosa: OCT Reading Center$256,633
UG1 · FY2025 · EY · contact PI
NAC Attack, a phase-3, multicenter, randomized, placebo-controlled trial with retinitis pigmentosa: OCT Reading Center$259,193
UG1 · FY2024 · EY · contact PI
NAC Attack, a phase-3, multicenter, randomized, placebo-controlled trial with retinitis pigmentosa: OCT Reading Center$255,340
UG1 · FY2023 · EY · contact PI
NAC Attack, a phase-3, multicenter, randomized, placebo-controlled trial with retinitis pigmentosa: OCT Reading Center$213,871
UG1 · FY2022 · EY · contact PI
Comparison of AMD Treatment Trials-OCT Reading Center$64,511
U10 · FY2013 · EY · contact PI
Comparison of AMD Treatment Trials-OCT Reading Center$177,792
U10 · FY2012 · EY · contact PI
Comparison of AMD Treatment Trials-OCT Reading Center$280,590
U10 · FY2011 · EY · contact PI
Comparison of AMD Treatment Trials-OCT Reading Center$166,659
U10 · FY2010 · EY · contact PI
Comparison of AMD Treatment Trials-OCT Reading Center$576,978
U10 · FY2009 · EY · contact PI
Comparison of AMD Treatment Trials-OCT Reading Center$136,288
U10 · FY2009 · EY · contact PI
Comparison of AMD Treatment Trials-OCT Reading Center$248,642
U10 · FY2008 · EY · contact PI
Comparison of AMD Treatment Trials-OCT Reading Center$302,976
U10 · FY2007 · EY · contact PI
Comparison of AMD Treatment Trials-OCT Reading Center$384,837
U10 · FY2006 · EY · contact PI
Cytokine Modulation in Proliferative Vitreoretinopathy$269,500
R01 · FY2005 · EY
Cytokine Modulation in Proliferative Vitreoretinopathy$269,500
R01 · FY2004 · EY
Cytokine Modulation in Proliferative Vitreoretinopathy$269,500
R01 · FY2003 · EY
Cytokine Modulation in Proliferative Vitreoretinopathy$269,500
R01 · FY2002 · EY
PH I: SUSTAINED RELEASE CYCLOSPORIN IMPLANT FOR UVEITIS$117,022
M01 · FY2002 · RR
Cytokine Modulation in Proliferative Vitreoretinopathy$70,825
R01 · FY2002 · EY
PH I: SUSTAINED RELEASE CYCLOSPORIN IMPLANT FOR UVEITIS$293,069
M01 · FY2001 · RR
PH I: SUSTAINED RELEASE CYCLOSPORIN IMPLANT FOR UVEITIS$117,022
M01 · FY2001 · RR
PH I: SUSTAINED RELEASE CYCLOSPORIN IMPLANT FOR UVEITIS$117,022
M01 · FY2001 · RR
CYTOKINE MODULATION IN PROLIFERATIVE VITREORETINOPATHY$197,804
R01 · FY2000 · EY
PH I: SUSTAINED RELEASE CYCLOSPORIN IMPLANT FOR UVEITIS$40,907
M01 · FY2000 · RR
PH I: SUSTAINED RELEASE CYCLOSPORIN IMPLANT FOR UVEITIS$0
M01 · FY2000 · RR